WO2000067787A3 - Hiv immunogenic compositions and methods - Google Patents

Hiv immunogenic compositions and methods Download PDF

Info

Publication number
WO2000067787A3
WO2000067787A3 PCT/US2000/012495 US0012495W WO0067787A3 WO 2000067787 A3 WO2000067787 A3 WO 2000067787A3 US 0012495 W US0012495 W US 0012495W WO 0067787 A3 WO0067787 A3 WO 0067787A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
immunogenic compositions
antigen
mammal
hiv antigen
Prior art date
Application number
PCT/US2000/012495
Other languages
French (fr)
Other versions
WO2000067787A2 (en
Inventor
Ronald B Moss
Original Assignee
Immune Response Corp Inc
Ronald B Moss
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp Inc, Ronald B Moss filed Critical Immune Response Corp Inc
Priority to AU49929/00A priority Critical patent/AU4992900A/en
Priority to CA002372960A priority patent/CA2372960C/en
Priority to APAP/P/2001/002300A priority patent/AP1891A/en
Priority to EP00932163A priority patent/EP1176978A2/en
Priority to BR0010323-3A priority patent/BR0010323A/en
Publication of WO2000067787A2 publication Critical patent/WO2000067787A2/en
Publication of WO2000067787A3 publication Critical patent/WO2000067787A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The invention provides immunogenic compositions which enhance beta-chemokine levels in a mammal. The immunogenic compositions contain an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The HIV antigen can be a whole-killed HIV virus devoid of outer envelope protein gp120. Alternatively, the HIV antigen can be a whole-killed HIV virus, or a p24 antigen. Also provided is a method of inhibiting AIDS, by enhancing beta-chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant.
PCT/US2000/012495 1999-05-06 2000-05-05 Hiv immunogenic compositions and methods WO2000067787A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU49929/00A AU4992900A (en) 1999-05-06 2000-05-05 Hiv immunogenic compositions and methods
CA002372960A CA2372960C (en) 1999-05-06 2000-05-05 Hiv immunogenic compositions and methods
APAP/P/2001/002300A AP1891A (en) 1999-05-06 2000-05-05 HIV immunogenic compositions and methods.
EP00932163A EP1176978A2 (en) 1999-05-06 2000-05-05 Hiv immunogenic compositions and methods
BR0010323-3A BR0010323A (en) 1999-05-06 2000-05-05 Immunogenic compositions, kit and method of making it for use in the immunization of a mammal

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13276299P 1999-05-06 1999-05-06
US60/132,762 1999-05-06
US15066799P 1999-08-25 1999-08-25
US60/150,667 1999-08-25

Publications (2)

Publication Number Publication Date
WO2000067787A2 WO2000067787A2 (en) 2000-11-16
WO2000067787A3 true WO2000067787A3 (en) 2001-04-26

Family

ID=26830710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012495 WO2000067787A2 (en) 1999-05-06 2000-05-05 Hiv immunogenic compositions and methods

Country Status (8)

Country Link
EP (1) EP1176978A2 (en)
AP (1) AP1891A (en)
AU (1) AU4992900A (en)
BR (1) BR0010323A (en)
CA (1) CA2372960C (en)
CR (1) CR6491A (en)
OA (1) OA11937A (en)
WO (1) WO2000067787A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028845B2 (en) 2001-06-21 2015-05-12 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same-IV
US9382545B2 (en) 2006-09-27 2016-07-05 Coley Pharmaceutical Gmbh CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK1077722T3 (en) 1998-05-22 2006-11-27 Ottawa Health Research Inst Methods and products for the induction of mucosa immunity
JP2003523721A (en) 1998-12-31 2003-08-12 カイロン コーポレイション Polynucleotides encoding antigenic HIVC-type polypeptides, polypeptides, and uses thereof
ATE464907T1 (en) 1999-02-17 2010-05-15 Csl Ltd IMMUNOGENIC COMPLEXES AND METHODS RELATING THEM
EP1198249B1 (en) * 1999-06-29 2005-10-19 GlaxoSmithKline Biologicals S.A. Use of cpg as an adjuvant for hiv vaccine
ATE471374T1 (en) 2000-12-27 2010-07-15 Dynavax Tech Corp IMMUNOMODULATORY POLYNUCLEOTIDES AND METHOD FOR USE THEREOF
WO2002058726A1 (en) * 2001-01-26 2002-08-01 The Immune Response Corporation Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment
KR100991644B1 (en) 2001-08-17 2010-11-02 콜리 파마슈티칼 게엠베하 Combination Motif Immune Stimulatory Oligonucleotides with Improved Activity
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
EP1551221A4 (en) * 2002-07-03 2007-08-01 Coley Pharm Group Inc Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
EP2241325B1 (en) 2002-10-29 2012-02-08 Coley Pharmaceutical Group, Inc. Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
JP2006512927A (en) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド 5 'CPG nucleic acids and methods of use thereof
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
DE60329223D1 (en) 2002-12-23 2009-10-22 Dynavax Tech Corp OLIGONUCLEOTIDES WITH AN IMMUNE SYSTEM STIMULATING SEQUENCE AND METHOD FOR THEIR APPLICATION
BRPI0413906A (en) * 2003-08-28 2006-10-24 Immune Response Corp Inc HIV immunogenic compositions, kit and related methods
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
WO2010051820A1 (en) * 2008-11-10 2010-05-14 Aarhus Universitet Multiplexed cytokine vaccination
CN103796639B (en) 2011-07-06 2017-05-31 诺华股份有限公司 Cation oil-in-water emulsion
JP6059220B2 (en) 2011-07-06 2017-01-18 ノバルティス アーゲー Oil-in-water emulsion containing nucleic acid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040100A1 (en) * 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040100A1 (en) * 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; MOSS R B ET AL: "Tumor necrosis factor alpha and human immunodeficiency virus -specific functional immune responses after immunization with Gp120 - depleted, inactivated HIV -1 in incomplete Freund 's adjuvant (REMUNE) in HIV -1-seropositive subjects.", XP002153410, retrieved from STN Database accession no. 1999211139 *
J HUM VIROL, (1998 JAN-FEB) 1 (2) 77-81. *
LANZA P ET AL: "Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 16, no. 7, 1 April 1998 (1998-04-01), pages 727 - 731, XP004112262, ISSN: 0264-410X *
MOSS RONALD B ET AL: "In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides.", VACCINE, vol. 18, no. 11-12, January 2000 (2000-01-01), pages 1081 - 1087, XP002153409, ISSN: 0264-410X *
SUN SIQUAN ET AL: "DNA as an adjuvant: Capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen", JOURNAL OF EXPERIMENTAL MEDICINE,TOKYO,JP, vol. 187, no. 7, 6 April 1998 (1998-04-06), pages 1145 - 1150, XP002148907, ISSN: 0022-1007 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028845B2 (en) 2001-06-21 2015-05-12 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same-IV
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins
US9382545B2 (en) 2006-09-27 2016-07-05 Coley Pharmaceutical Gmbh CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity

Also Published As

Publication number Publication date
AP1891A (en) 2008-09-23
EP1176978A2 (en) 2002-02-06
BR0010323A (en) 2002-01-08
CR6491A (en) 2005-05-31
OA11937A (en) 2006-04-12
AP2001002300A0 (en) 2001-12-31
CA2372960A1 (en) 2000-11-16
WO2000067787A2 (en) 2000-11-16
CA2372960C (en) 2006-03-28
AU4992900A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
WO2000067787A3 (en) Hiv immunogenic compositions and methods
EP1246644A4 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
NZ583028A (en) Nucleic acids and proteins from streptococcus groups A & B
WO2003080114A3 (en) Imidazoquinoline adjuvants for vaccines
WO2000057917A3 (en) Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
WO2001093902A3 (en) Immunostimulatory rna/dna hybrid molecules
WO2001044286A3 (en) Five-helix protein
WO2003063766A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP1568373A3 (en) Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
EP1144998A3 (en) Neisseria genomic sequences and methods of their use
WO2002020554A3 (en) Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines
MXPA01011047A (en) Neisseria genomic sequences and methods of their use.
WO2002060926A3 (en) Hepatitis c tripeptide inhibitors
WO2003082183A3 (en) Protein-based streptococcus pneumoniae vaccines
NO20011282D0 (en) New influenza virus vaccine preparation
IL145982A0 (en) Vaccines
KR970705403A (en) A non-toxic oral adjuvant that is an effective enterotoxin mutant (MUTANT ENTEROTOXIN EFFECTIVE AS A NON-TOXIC ORAL ADJUVANT)
WO2001000232A3 (en) Use of cpg as an adjuvant for hiv vaccine
WO2002032943A3 (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
WO2005013918A3 (en) Compositions, methods and kits relating to poxvirus subunit vaccines
WO2000050075A3 (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
EP0830456A4 (en) ISOLATED FrpB NUCLEIC ACID MOLECULE AND VACCINE
WO2005021726A3 (en) Immunogenic hiv compositions and related methods
WO2001070265A3 (en) Lipopeptide adjuvants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001/08559

Country of ref document: ZA

Ref document number: 200108559

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/010784

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 49929/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2372960

Country of ref document: CA

Ref document number: 2372960

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/01083/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2000932163

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000932163

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP